arrow
J

Jerald P. Radich

Fred Hutchinson Cancer Research Center
H指数:98
被引数:5.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia

异基因移植前急性髓系白血病中可测量的残留突变NPM1

2025-11-240
OAAI
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

2025欧洲白血病网关于慢性粒细胞白血病治疗的建议

Leukemia
IF13.4
2025-07-110
OA
Analytical Performance of the NCI-myeloMATCH Assay

NCI-myeloMATCH检测方法的性能分析

2025-05-150
PRE
Genomic Proximity Mapping (GPM): Evaluation of a Next Generation Cytogenomic Assay for Improved Risk Stratification in Acute Myeloid Leukemia

基因组邻近图谱(GPM):下一代细胞基因组学检测方法在急性髓系白血病风险分层改进中的评估

BLOOD
IF23.1
2024-11-050
PRE
Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

培美曲塞联合阿扎胞苷和维奈克拉用于急性髓系白血病患者的疗效与安全性:一项研究者发起、多中心、CTEP资助的随机、Ⅱ期试验(BLAST AML-2)的结果

BLOOD
IF23.1
2024-11-050
PRE
Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

急性髓系白血病异基因移植前的可测量残留NPM1突变

BLOOD
IF23.1
2024-11-050
PRE
Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

NPM1突变急性髓系白血病中ELN2022风险分层的评估:一项来自Fred Hutch和SWOG的研究

BLOOD
IF23.1
2024-11-050
PRE
Recommendations from the AML molecular MRD expert advisory board
LEUKEMIA
IF13.4
2024-05-230
OAAI